回顾性分析 10 多年来在沙特阿拉伯进行的 Mohs 显微外科手术趋势。
A retrospective review of Mohs micrographic surgery trends over more than 10 years in Saudi Arabia.
机构信息
From the Department of Dermatology (Alsharif, AlFada), College of Medicine, King Saud University; and from the Department of Dermatology (Alaqeel), College of Medicine, Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia.
出版信息
Saudi Med J. 2023 Jul;44(7):667-673. doi: 10.15537/smj.2023.44.7.20220892.
OBJECTIVES
To review Mohs micrographic surgery (MMS) trends in Saudi Arabia.Mohs micrographic surgery is a precise surgical technique that has been proven to have the highest cure rate with maximum normal tissue preservation. It is the treatment of choice for non-melanoma skin cancer (NMSC), especially the aggressive histopathological forms, and tumors located in high-risk regions or where tissue preservation is a mandate.
METHODS
A multicentric retrospective study was performed on patients who underwent MMS between January 2010 and September 2022. The information was extracted from the database of King Saud University Medical City and Prince Sultan Military Medical City in Saudi Arabia.
RESULTS
A total of 70 participants were enrolled in this study. Two-thirds (67%) of the tumors that were treated using MMS were basal-cell carcinomas (BCC), 18.6% were squamous cell carcinomas (SCC), 5.7% were sebaceous carcinoma, 4.3% were dermatofibrosarcoma protuberans (DFSP), and 1.4% were rare tumors such as primary mucinous carcinoma. The most common type of reconstruction used to repair post-MMS defect was primary closure in more than half of the patients followed by secondary intention healing (20%). There were no side effects apart from a hematoma in one patient and wound infection in two patients.
CONCLUSION
Although MMS is still generally underutilized in Saudi Arabia, its use has increased in the last decade.
目的
回顾沙特阿拉伯的 Mohs 显微外科手术(MMS)趋势。Mohs 显微外科手术是一种精确的外科技术,已被证明具有最高的治愈率和最大限度的正常组织保留率。它是治疗非黑色素瘤皮肤癌(NMSC)的首选方法,特别是侵袭性组织病理学形式的肿瘤,以及位于高风险区域或需要保留组织的肿瘤。
方法
对 2010 年 1 月至 2022 年 9 月期间在沙特阿拉伯的 King Saud 大学医学城和 Prince Sultan 军事医学城接受 MMS 治疗的患者进行了一项多中心回顾性研究。信息从数据库中提取。
结果
共有 70 名患者纳入本研究。接受 MMS 治疗的肿瘤中,三分之二(67%)为基底细胞癌(BCC),18.6%为鳞状细胞癌(SCC),5.7%为皮脂腺癌,4.3%为隆突性皮肤纤维肉瘤(DFSP),1.4%为罕见肿瘤,如原发性黏液腺癌。用于修复 MMS 后缺陷的最常见重建类型是超过一半患者的一期闭合,其次是二期愈合(20%)。除了一名患者出现血肿和两名患者出现伤口感染外,没有其他副作用。
结论
尽管 MMS 在沙特阿拉伯的应用仍普遍不足,但在过去十年中,其应用有所增加。
相似文献
Cancer Treat Rev. 2008-12
引用本文的文献
Healthcare (Basel). 2025-6-6
本文引用的文献
J Am Acad Dermatol. 2021-4
JAMA Facial Plast Surg. 2019-9-1